TrialsgrambetaRCTs are beautiful

OVERCOME

2013

PreventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies

In 90 patients with malignant haemopathies undergoing intensive chemotherapy or autologous stem-cell transplantation, enalapril plus carvedilol started before chemotherapy preserved left ventricular ejection fraction and reduced death or heart failure at 6 months compared with no cardioprotective treatment.

Result

Primary endpoint: Absolute change in left ventricular ejection fraction at 6 months

LVEF unchanged with treatment but reduced in controls (between-group difference −3.1 %; p=0.035). Death or heart failure 6.7 % vs 22 % (p=0.036).

Original publication
Subtopic
Neurohormonal prophylaxis
Design
Randomised controlled trial with an untreated control group
Relevance
Supporting: context rather than must-know.
Source
Bosch X, Rovira M, Sitges M, et al. J Am Coll Cardiol. 2013;61(23):2355-2362.doi 10.1016/j.jacc.2013.02.072

Discussion & critique

Very small, single-centre, with an untreated rather than placebo control and a composite built on few events, so the clinical benefit is fragile. It is the only randomised cardioprotection trial to reduce a clinical composite of death or heart failure and is the strongest pillar of combined ACE-inhibitor plus beta-blocker prophylaxis.